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longed recovery, or death. Heparin coating of the
blood-contact surfaces of cardiopulmonary bypass
(CPB) equipment may reduce this inflammatory reac-
Contact between blood and the foreign surfaces of aheart-lung machine evokes a systemic inflammato-
ry reaction that may result in organ dysfunction, pro-
Objectives: 1. To study possible clinical benefits of heparin-coated car-
diopulmonary bypass in patients with a broad range of preoperative
risk factors. 2. To evaluate the correlation between the terminal com-
plement complex and clinical outcome. 3. To identify clinical predictors
of complement activation and correlates of granulocyte activation dur-
ing cardiac surgery. Methods: Blood samples from adults undergoing
elective cardiac surgery with Duraflo II heparin-coated (n = 81) or
uncoated (n = 75) cardiopulmonary bypass sets (Duraflo coating sur-
face; Baxter International, Inc, Deerfield, Ill) were analyzed for activa-
tion of complement (C3 activation products, terminal complement com-
plex), granulocytes (myeloperoxidase, lactoferrin), and platelets
(b -thromboglobulin) by enzyme immunoassays. Preoperative risk was
assessed by means of the “Higgins’ score.” Complications (cardiac,
renal, pulmonary, gastrointestinal, and central nervous system dysfunc-
tion, infections, death) were registered prospectively. Data were ana-
lyzed by analysis of variance, logistic regression, and linear regression.
Results and conclusions: Sixty-seven percent of the patients had predefined
risk factors. Complications developed in 53 patients (34%), equivalent-
ly with and without heparin-coated bypass sets (P = .44-.82), despite a
significant reduction in complement and granulocyte activation by
heparin coating. No clear-cut relationship between the terminal comple-
ment complex and outcome was found, even if it was significant in the
models for renal and central nervous system dysfunction and infections
(P = .006). The Higgins’ score was significantly related to complement
activation (P < .05). Approximately 50% of the variation in granulocyte
activation was explained by complement (P ≤ .01) and platelet activation
(P < .05), heparin/protamine dose ratio (P = .02), duration of cardiopul-
monary bypass (P < .01), and gender (P < .05). Therefore measures
reducing complement activation alone will not necessarily reduce gran-
ulocyte activation sufficiently for clinical significance. (J Thorac
Cardiovasc Surg 1999;117:794-802)
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tion. Despite reports of reduced neutrophil,1 eosino-
phil,2 monocyte,1 platelet,3 complement,4 and contact
activation5 and decreased cytokine release,6 few stud-
ies have been able to demonstrate significant clinical
benefits from heparin coating. However, most studies
were small, increasing the risk of drawing false nega-
tive conclusions. Furthermore, many studies included
low-risk patients, rendering differences more or less
impossible to detect because of low overall postopera-
tive morbidity and mortality, as in the Duraflo II
Multicentre Study.7 The first aim of the present study
was therefore to investigate possible clinical benefits
of heparin coating with full systemic heparinization
when including patients with a broad range of preop-
erative risk factors. 
Complement activation is often used when compar-
ing “biocompatibility” of CPB setups, that is, the extent
of the evoked inflammatory reaction. Activated com-
plement may directly induce tissue damage. The clini-
cal relevance of measuring complement activation rests
mainly on the study by Kirklin and coworkers8 from
1983, showing correlations between plasma C3a con-
centrations and organ dysfunction. Presently, a number
of sensitive immunoassays for complement activation
at various levels of the cascade are available. In vitro
studies have shown that quantitation of the terminal
SC5b-9 complement complex (TCC) very sensitively
discriminates between different CPB setups.9 The sec-
ond aim of the study was to evaluate whether TCC
measurements are related to clinical outcome.
In vitro, there are great individual differences in
degree of complement activation on a given stimulus,
and activation during CPB also varies substantially
among individuals.4 The third aim of the study was to
identify clinical predictors of increased complement
activation. 
Granulocyte activation is regarded as an important
link between many inflammatory mediators formed
during CPB and organ damage. Activated granulocytes
adhere to the activated vascular endothelium and release
a host of substances further damaging the endothelial
cells, permitting edema formation and extravasation of
granulocytes. Activated complement is a significant fac-
tor responsible for granulocyte activation during CPB.
Other potential granulocyte activators are also present
(eg, endotoxin, various cytokines, and platelet activation
products), but their relative importance is unknown. The
fourth aim of the investigation was to find correlates of
granulocyte activation during cardiac surgery.
Data from a subgroup of 29 patients, in whom we
explored mechanisms for the reduced complement acti-
vation observed using heparin-coated CPB circuitry,
are presented separately.10
Patients and methods
Patients and perfusion management. A total of 156
adults admitted for elective cardiac surgery at the National
Hospital were included in the study after giving informed
consent. To achieve a study population including both low-
risk and high-risk patients, we entered consecutive patients in
the study if they belonged to one of the following groups: 51
patients (low-risk group) scheduled for coronary bypass
surgery, with no major noncardiac illness and a left ventricu-
lar ejection fraction of 0.40 or more; 105 patients (high-risk
group) who had significant noncardiac illness (eg, diabetes,
chronic obstructive pulmonary disease, renal insufficiency,
cerebrovascular disease) or a preoperative left ventricular
ejection fraction less than 0.40 or who were scheduled for
valve replacement or coronary bypass surgery combined with
either valve replacement or carotid artery endarterectomy.
Exclusion criteria were ongoing infections, liver failure, and
use of steroids or nonsteroid anti-inflammatory agents except
acetylsalicylic acid. 
Patients were randomized to CPB with one of the follow-
ing setups:
• Heparin-coated group (n = 81): Univox oxygenator and
tubing/connectors, cardiotomy suction, and a 25-mm arteri-
al line screen filter (Bentley/Baxter, Uden, The Netherlands)
with the entire blood-contact surface heparin-coated by the
Duraflo II method (ionically bound heparin) (Baxter
International, Inc, Deerfield, Ill)
• Uncoated group (n = 75): Uncoated, otherwise similar oxy-
genator, tubing, and filter set
The extracorporeal circuit was primed with 1800 mL
Ringer’s acetate solution containing 5000 IU heparin. Before
CPB, 300 IU heparin per kilogram of body weight was
administered intravenously in both groups. Additional
heparin was given if needed to maintain an activated clotting
time of 480 seconds or more. Cardiotomy suction and a non-
pulsatile roller pump were used in all patients. Cold St
Thomas’ Hospital cardioplegic solution was used in addition
to local cooling and moderate general hypothermia (30°C-
32˚C). After CPB, 1 mg of protamine was administered for
each 100 IU of heparin. Additional protamine was given if
necessary to re-establish preoperative activated clotting time. 
Registered variables. Age, gender, height, weight, preop-
erative condition, noncardiac illness, and medication were
registered on admission. Type of operation, total heparin and
protamine administration, duration of the operation, CPB,
and aortic occlusion, chest tube drainage, and transfusions
were recorded. The following postoperative complications
were registered prospectively according to defined criteria:
Infective complications: Wound infection, pneumonia, medi-
astinitis, or sepsis
Cardiac dysfunction: Sustained need for epinephrine or intra-
aortic balloon pump to maintain adequate blood pressure
Renal dysfunction: Serum creatinine level greater than 200
m mol/L and/or anuria in patient with normal preoperative
kidney function
Adult respiratory distress syndrome: Arterial oxygen tension
less than 10 kPa with inspired oxygen fraction greater than
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0.5 and bilateral chest effusions on x-ray films, without
indications of cardiac failure 
Gastrointestinal dysfunction: Bilirubin level greater than 50
m mol/L or acute gastrointestinal bleeding
Central nervous system dysfunction: Peripheral paralysis
Death: During primary hospital stay without recovery after
operation, that is, “hospital mortality”11
The patient’s preoperative risk status was summarized with
the use of the clinical severity score published by Higgins and
coworkers,12 denoted as the “Higgins’ score.”
Blood samples and analyses. Samples with or without
anticoagulants were obtained just before systemic hepariniza-
tion, after 30 minutes of CPB, at termination of CPB, during
closure of the skin over the sternum, and 3 hours after the
operation. The exact sampling times were recorded. All tubes
containing anticoagulants were kept on ice until centrifuga-
tion within 8 hours. Plasma or serum was stored at –70°C. 
Hemoglobin, hematocrit, and blood cell counts were deter-
mined in an automated analyzer (Technicon H-1, Miles,
Tarrytown, NY).
Complement activation measured as C3 activation products
(C3bc), C5a-desArg, and TCC was quantitated in enzyme
immunoassays in ethylenediaminetetraacetic acid plasma.13
Granulocyte activation was analyzed with the use of
enzyme immunoassays specific for the degranulation prod-
ucts myeloperoxidase (MPO) and lactoferrin (LF) in ethyl-
enediaminetetraacetic acid plasma.14,15
Platelet degranulation was assessed by determination of b -
thromboglobulin (BTG) in citrate-theophylline-adenosine-
dipyridamole–containing plasma (Diatube-H, Diagnostica
Stago, Asnieres-sûr-Seine, France) in a novel competitive
enzyme immunoassay (see appendix). 
Endotoxin was analyzed in heparin-anticoagulated samples
drawn into pyrogen-free tubes at termination of CBP (n =
136) by Limulus amebocyte lysate assay (Chromogenix,
Endosafe, Charleston, SC). 
To obtain a preoperative complement profile of each
patient, we quantitated C3 and C4 antigen in the baseline
serum samples by nephelometry (Behring laser nephelome-
ter, Behringwerke AG, Marburg, Germany) according to the
manufacturer’s instructions. Classical (CH50-c) and alterna-
tive (CH50-a) total hemolytic complement activity were mea-
sured by means of microwell techniques.16
No measurements were corrected for hemodilution. 
Statistics. Data are given as mean with 95% confidence
intervals in parenthesis. For the complement, granulocyte,
and platelet activation data, the highest concentration for each
patient irrespective of time of occurrence was identified and
denoted “maximal C3bc,” “maximal TCC,” and so on, in the
following. As a summary measure, the area under the time
curve for the activation parameters was calculated for each
patient and is denoted “C3bc area,” “TCC area,” and so on.17
The activation parameters were analyzed with 2-way
repeated-measures analysis of variance (ANOVA) after loga-
rithmic transformation, using duration of CPB as a covariate.
Other comparisons of variables between groups were per-
formed with the c 2 test, Fisher’s exact test, 2-tailed t test, or
ANOVA, or with the Mann-Whitney U test or Kruskal-Wallis
test if not normally distributed.
Factors correlated to each complication were identified
with standard methods for logistic regression using the
SPSS program package (SPSS, Inc, Chicago, Ill). Linear re-
gression identifying clinical predictors of complement acti-
vation and correlates of granulocyte activation was per-
formed by means of standard methods in SPSS (details in
the appendix).
The study was approved by the regional ethical committee
on February 25, 1993.
Table I. Patient characteristics and variables pertaining to operation
Operation CABG Valve replacement CABG and valve CABG and vascular P value
No. of patients 82 24 41 9
Women 6 (7%) 11 (46%) 14 (34%) 2 (22%) .001
Age (y) 63 (61-65) 68 (64-71) 66 (62-69) 68 (64-71) .12
Weight (kg) 80 (78-83) 76 (70-83) 71 (67-74) 77 (69-84) .003
Higgins’ score 3.1 (2.4-3.8) 3.6 (2.7-4.6) 3.8 (2.9-4.7) 4.3 (1.8-6.9) .42
Diabetes 10 (12%) 5 (21%) 3 (7%) 1 (11%) .46
Previous CNS symptom 10 (12%) 0 (0%) 3 (7%) 5 (56%) .001
COPD 2 (2%) 3 (13%) 7 (17%) 0 (0%) .02
Hypertension 15 (18%) 6 (25%) 9 (22%) 1 (11%) .78
Renal dysfunction 5 (6%) 1 (4%) 2 (5%) 0 (0%) .87
Compensated cardiac insufficiency 12 (15%) 11 (46%) 10 (24%) 1 (11%) .001
Redo operation 19 (23%) 1 (4%) 6 (17%) 1 (11%) .46
Aortic occlusion time (min) 35 (32-38) 63 (55-72) 74 (66-81) 34 (29-39) <.001
CPB duration (min) 72 (69-77) 94 (85-103) 132 (110-154) 69 (57-80) <.001
Time on respirator (h) 18.4 (5.8-31.1) 10.6 (3.2-18.1) 19.9 (2.9-36.9) 6.0 (4.4-7.5) .81
Thoracic drainage (mL) 1080 (895-1266) 693 (516-871) 1223 (788-1658) 1089 (687-1491) .20
CABG, Coronary artery bypass surgery; CABG and valve, coronary artery bypass surgery and valve replacement; CABG and vascular, coronary artery bypass surgery
and carotid artery endarterectomy; P value was determined by the c 2 test, ANOVA, or Kruskal-Wallis test; CNS, central nervous system; COPD, chronic obstructive
pulmonary disease; CPB, cardiopulmonary bypass.
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Results
Patient and operative variables (Table I). Four
groups of operative procedures were considered: coro-
nary bypass surgery (CABG, n = 82), valve replace-
ment (valve, n = 24), coronary bypass surgery com-
bined with valve replacement (CABG + valve, n = 41),
and coronary bypass surgery combined with carotid
artery surgery (CABG + vascular, n = 9). As expected,
there were significant differences among these groups
with respect to gender, body weight, aortic occlusion
times, and duration of CPB. 
The patients in the heparin-coated and uncoated
groups were comparable with respect to gender, age,
Higgins’ score, type of operation, diabetes, previous
central nervous system symptoms, chronic obstructive
pulmonary disease, hypertension, renal dysfunction,
compensated cardiac insufficiency, redo operation, aor-
tic occlusion, CPB duration, and heparin and protamine
doses (P = .18-.93). 
The mean Higgins’ score was 3.4 (3.0-3.9). Sixty-
nine patients (44%) had scores of more than 3, and 34
patients (22%) had scores of more than 5, confirming
that our study included a large proportion of high-risk
patients.
Complications (Table II). One hundred three
patients (66%) had an uneventful recovery. Fifty-three
patients (34%) experienced one or more complications,
including revisions for bleeding. Twenty-four reopera-
tions were necessitated by surgical bleeding (n = 12),
bleeding caused by generalized oozing (n = 6), medi-
astinitis (n = 4), paravalvular leakage (n = 1), and endo-
carditis (n = 1). No patients fulfilled the criteria for
adult respiratory distress syndrome. Seven patients
died before the tenth postoperative day, 1 on day 20,
and 1 on day 36. There were no significant differences
Table II. Postoperative complications* 
All patients Uncoated CPB set Heparin-coated CPB set P value†
Cardiac dysfunction 20 (13%) 9 (12%) 11 (14%) .82
CNS dysfunction 8 (5%) 3 (4%) 5 (6%) .56
Renal dysfunction 11 (7%) 4 (5%) 7 (9%) .44
Infection 21 (14%) 12 (16%) 9 (11%) .56
Wound infection 3 (4%) 5 (6%) .56
Pneumonia 7 (10%) 6 (7%) .57
Sepsis 0 (0%) 2 (2%) .50
Mediastinitis 4 (5%) 1 (1%) .14
Gastrointestinal dysfunction 3 (2%) 2 (3%) 1 (1%) .50
Reoperation 25 (16%) 13 (18%) 12 (15%) .55
Death 9 (6%) 5 (7%) 4 (5%) .64
CPB, Cardiopulmonary bypass; CNS, central nervous system.
*Two patients who died during the operation were not included in analysis of other complications.
† c 2 Test or Fisher’s exact test. 
Table III. Maximal and summary measures of activation parameters
Parameter Uncoated CPB set Heparin-coated CPB set P value*
Maximal MPO concentration (µg · L–1) 872 (802-942) 783 (730-837) .09
Area under MPO curve (µg · L–1 · min · 103) 205 (178-232) 183 (165-200) .22
Maximal LF concentration (µg · L–1) 1101 (963-1239) 902 (810-994) .03
Area under LF curve (µg · L–1 · min · 103) 250 (206-294) 198 (173-223) .14
Maximal C3bc concentration (AU · mL–1) 103 (93-114) 93 (81-105) .07
Area under C3bc curve (AU · mL–1 · min · 103) 23.9 (21.5-26.4) 19.3 (16.9-21.8) .01
Maximal C5a-desArg concentration (ng · mL–1) 14.5 (12.3-16.6) 16.3 (12.9-19.8) .22
Area under C5a-desArg curve (ng · mL–1 · min · 102) 39.6 (33.6-45.6) 44.6 (34.3-54.9) .54
Maximal TCC concentration (AU · mL–1) 6.4 (5.8-7.0) 3.9 (3.5-4.4) .001
Area under TCC curve (AU · mL–1 · min · 103) 1.3 (1.1-1.4) 0.8 (0.7-0.9) .001
Maximal BTG concentration (ng · mL–1) 875 (617-1132) 828 (646-1009) .79
Area under BTG curve (ng · mL–1 · min · 103) 159 (122-195) 149 (121-178) .99
CPB, Cardiopulmonary bypass; MPO, myeloperoxidase; LF, lactoferrin; AU, arbitrary units; TCC, terminal compliment complex; BTG, b -thromboglobulin.
*Mann-Whitney U test.
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between the heparin-coated and uncoated groups for
any complication (Table II) or in total thoracic drainage
(uncoated, 1109 mL [895-1324 mL]; heparin-coated,
1020 mL [798-1242 mL]; P = .57) or duration of res-
piratory support (uncoated, 18 hours [7-28 hours];
heparin-coated, 16 hours [4-29 hours]; P = .88). 
Blood tests. By ANOVA, there were no differences
in hemoglobin concentration (P = .52), but leukocytes
tended to be fewer in the uncoated group (P = .07)
(data not shown). Platelet numbers decreased from
181 · 109/L (171-191 · 109/L) to 113 · 109/L (104-
121 · 109/L (uncoated) and 180 · 109/L (170-190 ·
109/L) to 123 · 109/L (116-130 · 109/L) (heparin-
coated) after 30 minutes of CPB, and there were no
differences in platelet numbers by ANOVA (P = .50). 
Activation parameters are shown in Table III. By
ANOVA using CPB duration as covariate, differences
in LF (P < .05), C3bc (P < .0005), and TCC (P < .0005)
between the heparin-coated and uncoated groups were
significant (Figs 1 to 3). 
Baseline C3bc, TCC, C3 and C4 antigen, CH50-c, and
CH50-a were within normal ranges (data not shown).
Logistic regression models (Table IV). No model
was fitted for gastrointestinal dysfunction (n = 3). For
death, only maximal concentrations of the activation
parameters were used during model fitting, because
some patients died before all samples were drawn. For
all models, fit was good by the Hosmer-Lemeshow test.
If only the MPO, TCC, and BTG variables were includ-
ed instead of all the activation parameters, a substantial
loss of model significance and fit was observed (data
not shown).
Regression models for complement and granulo-
cyte activation. All complement activation parameters
were significantly correlated to the Higgins’ score (P <
.001-.05) and use of uncoated CPB set (P < .0005-.02),
but the percentage of variation explained by the models
(R2) was less than 35% (data not shown). The models
Fig 1. Granulocyte activation measured as plasma lactoferrin
(LF, m g/L) during cardiac surgery in 156 patients using
heparin-coated (n = 81) or uncoated (n = 75) CPB circuits.
Data are mean with 95% confidence interval by mean sam-
pling time in each treatment group. Arrows show start and
termination of CPB in each group. Statistical comparisons by
ANOVA after logarithmic transformation: Intergroup differ-
ences: P = .32; LF changes by time: P < .0005; group by LF
change interaction: P < .0005. LF concentrations were sig-
nificantly lower with heparin coating at termination of CPB
and at closure of the wound over the sternum (*P < .05).
Fig 2. Complement C3 activation measured as plasma C3bc
(arbitrary units per milliliter) during cardiac surgery in 156
patients using heparin-coated (n = 81) or uncoated (n = 75)
CPB circuits. Data are mean with 95% confidence intervals
by mean sampling time in each treatment group. Arrows
show start and termination of CPB in each group. Statistical
comparisons by ANOVA after logarithmic transformation:
Intergroup differences: P < .0005; C3bc changes by time: P
< .0005; group by C3bc change interaction: P = .01.
Fig 3. Complement activation measured as plasma TCC
(arbitrary units per milliliter) during cardiac surgery in 156
patients using heparin-coated (n = 81) or uncoated (n = 75)
CPB circuits. Data are mean with 95% confidence intervals
by mean sampling time in each treatment group. Arrows
show start and termination of CPB in each group. Statistical
comparisons by ANOVA after logarithmic transformation:
Intergroup differences: P < .0005; TCC changes by time: P <
.0005; group by TCC change interaction: P < .0005.
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for C3bc area, maximal TCC, and TCC area were
slightly improved by including duration of CPB or aor-
tic occlusion, whereas inclusion of other intraoperative
variables (heparin or protamine doses, or whether the
patient required more than one attempt at weaning from
CPB) gave no improvement. 
Significant variables explaining the granulocyte
activation parameters included complement and
platelet activation, heparin/protamine dose ratio,
duration of CPB, and gender (Table V). The models
explained approximately 50% of the variation in MPO
area and LF area, but less than 35% of the variation in
maximal MPO and LF. The models were not im-
proved by including the other intraoperative variables
mentioned above, and plasma endotoxin concentra-
tions at termination of CPB were not correlated to
granulocyte activation. 
Discussion
Clinical benefit of heparin coating. Our investiga-
tion included a substantial proportion of patients hav-
ing elevated Higgins’ scores, and we observed a num-
ber of postoperative complications. Even so, there were
no differences (P > .44) in number of complications
Table V. Linear regression models for granulocyte activation 
Dependent variable* Explanatory variables P value Coefficient SE R2 for model
Maximal MPO concentration Area under TCC curve* .001 0.15 0.042 0.17
Female gender .02 0.15 0.061
Area under BTG curve .04 0.039 0.019
MPO area Area under TCC curve <.0005 0.23 0.04 0.49
CPB duration · 10–1 <.0005 0.040 0.008
Area under BTG curve* .01 0.088 0.035
Female gender .03 0.14 0.064
Maximal LF concentration Area under C3bc curve <.0005 0.14 0.033 0.32
Area under BTG curve* <.0005 0.18 0.044
Female gender .004 0.25 0.085
Heparin/protamine dose ratio .02 0.72 0.32
LF area Area under BTG curve* <.0005 0.20 0.047 0.48
Female gender .003 0.28 0.089
Area under TCC curve .009 0.19 0.070
Area under C3bc curve .01 0.12 0.044
CPB duration* .01 0.31 0.12
SE, Standard error; MPO, myeloperoxidase; TCC, terminal complement complex; BTG, b -thromboglobulin; LF, lactoferrin; CPB, cardiopulmonary bypass.
*Transformation: logarithmic.
Table IV. Logistic regression models for complications
Complication Variable P value* Coefficient SE
Death Maximal BTG .0003 0.0010 0.0003
Maximal C5a-desArg .02 –0.23 0.12
Infections Area under LF curve .003 0.0079 0.0028
Area under TCC curve† .006 –3.0 0.94
Cardiac dysfunction Re-instituted CPB‡ .0001 4.6 1.5
Age .04 0.065 0.034
Area under TCC curve .08 0.66 0.36
Renal dysfunction Area under LF curve§ .004 0.0072 0.0055
Maximal TCC .006 –0.073 0.043
Maximal BTG .05 1.3 0.7
CNS dysfunction CABG + vascular operationsII .0003 3.0 0.96
Area under TCC curve .006 1.1 0.39
SE, Standard error; BTG, b -thromboglobulin; LF, lactoferrin; TCC, terminal complement complex; CPB, cardiopulmonary bypass; CNS, central nervous system;
CABG, coronary artery bypass surgery.
*Likelihood ratio test.
†Coded as above or below the median concentration.
‡CPB re-instituted during weaning because of cardiac failure.
§Transformations: LF and TCC, squared; BTG, logarithmic.
IICombined CABG and vascular operations compared with all other operations.
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between the patients treated with Duraflo II heparin-
coated and uncoated CPB circuits. This is in keeping
with the relatively few previous reports of improved
clinical outcome with heparin-coated CBP devices.18-20
Reduced systemic heparinization may increase the ben-
efits of heparin coating,21 pointing at heparin- and pro-
tamine-induced effects on the body’s defense systems
as more harmful than previously acknowledged.
However, not all agree that reduction of systemic
heparin is sufficiently safe. We used full systemic
heparinization in both groups to study only one vari-
able—heparin coating. 
Our study demonstrates that significant differences in
biochemical markers cannot directly be interpreted into
clinical relevance, even in a study including more than
150 patients and a fair number of outcome “events.”
Obviously, very many different factors may contribute
to post-CPB morbidity and mortality in each patient,
not all of which are related to biocompatibility. The
present knowledge about pathogenesis is probably
fragmentary, rendering it difficult to find efficient mea-
sures to reduce risk. 
TCC and clinical outcome. No clear-cut relation-
ship between TCC and clinical outcome was found,
even if TCC was significant in the logistic regression
models for infections, renal dysfunction, and central
nervous system dysfunction. The logistic regression
model coefficients should be interpreted cautiously in a
study of 156 patients. The TCC concentration had a
negative coefficient in the models for infections and
renal dysfunction. Thus the patients with less TCC for-
mation were at higher risk for the development of these
complications. The explanation for this finding is
unknown. Maybe the shape of the activation curve is of
importance, for example, whether the patient responds
with a rapid, intense production of TCC that peaks
early or tends to produce less TCC per unit of time, but
over a longer period. 
For central nervous system dysfunction and cardiac
dysfunction, the activation parameters significantly
improved models including widely known risk factors
such as carotid artery surgery and difficult weaning
from CPB, respectively. Most variables that were test-
ed other than the activation parameters had P values of
much more than .20 (data not shown). Thus, as a
whole, the indicators of complement, granulocyte, and
platelet activation were all clinically relevant parame-
ters of biocompatibility, but each marker including
TCC had varying significance with respect to the dif-
ferent complications. Whether inclusion of activation
markers of other cellular and humoral defense systems
such as endothelial cells, monocytes, coagulation, and
fibrinolysis improves assessment of biocompatibility,
warrants further study.
Clinical predictors of complement activation. Our
study clearly showed that the present knowledge of
individual factors influencing complement activation
during cardiac surgery is insufficient. The Higgins’
score was a significant explanatory variable for all com-
plement activation parameters. To our knowledge, this
is a new observation. The Higgins’ score was developed
for patients undergoing CABG.12 We used it for all
patient groups because it is a well-established risk score
predicting postoperative morbidity, not only mortality,
in cardiac surgical patients, and testing of each potential
risk factor itself would necessitate a much larger study
population. The risk factors included in the Higgins’
score were picked because of their proven relationship
with postoperative complications and mortality. Perhaps
one reason that these factors carry such an increased
risk is their tendency to influence complement activa-
tion. Six of the 13 variables in the Higgins’ score (ie,
reduced left ventricular ejection fraction, prior vascular
surgery, chronic obstructive pulmonary disease, anemia,
operative aortic stenosis, and diabetes) are related to an
increased risk of reduced peripheral oxygenation.
Ischemia is known to induce complement activation,22
and patients with these conditions may have a relative
tissue ischemia during CPB, increasing complement
activation. Furthermore, patients with reduced organ
function in the preoperative period may be more sus-
ceptible to complement-related damage, giving them an
additional disadvantage.
Correlates of granulocyte activation. Inclusion of
markers of contact activation might have further
improved the regression models. An important ex-
planatory variable for granulocyte activation in addi-
tion to complement activation was duration of CPB.
Ischemia in the lower part of the body, including the
abdomen, is likely during crossclamping. Release of
mediators from ischemic tissues on reperfusion acti-
vates the coagulation and fibrinolytic systems23 and
may also activate granulocytes.24
Granulocyte activation and release of BTG from
platelets were significantly correlated. These cells may
both activate and inhibit each other, but in general they
tend to positively stimulate activation of one another
during CPB.25 The present study demonstrates that
platelet-induced granulocyte activation is of practical
importance.
Protamine neutralizes heparin by reversible complex
formation. Heparin may later be released, because pro-
tamine has a shorter half-life than heparin.26 In vitro,
heparin preincubation results in more extensive granu-
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locyte activation on later stimulation with the comple-
ment-analog N-formyl-met-leu-phe.14 Granulocyte
activation was correlated to the heparin/protamine dose
ratio, with relatively more heparin increasing activa-
tion. The clinical significance of heparin-induced gran-
ulocyte activation is supported by previous observation
of reduced granulocyte activation with heparin-coated
CPB only accompanied by reduced systemic heparin,
whereas complement activation decreased also with
full systemic heparinization.27
Female gender was an additional significant variable
for granulocyte activation. Women carry a higher com-
plication risk after cardiac surgery, in part because they
tend to be sicker before the operation.28 On the basis of
our investigation, increased granulocyte activation may
be one factor increasing the risk of complications in
women. 
Our study demonstrates that granulocyte activation
during cardiac surgery is multifactorial. Therefore mea-
sures reducing complement activation alone may not be
sufficient to achieve a clinically relevant reduction in
postoperative organ dysfunction. 
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Appendix
BTG immunoassay. The plates were coated with partly
purified BTG from activated human platelets. Samples and
biotinylated (Biotinylation kit, Sigma Chemical Co, St Louis,
Mo) antihuman BTG antibody (Biogenesis, Poole, Dorset,
United Kingdom) were added, and peroxidase-conjugated
avidin (Zymed Laboratories, San Francisco, Calif) was added
in the final step. The substrate was o-phenylenediamine dihy-
drochloride (Sigma), and optical density was read at 490 nm
in a microtiter plate reader (ELX800, Bio-Tec Instruments,
Winooski, VT). Purified BTG from human platelets (Celsus
Laboratories, Cincinnati, Ohio) was used as standard.
Logistic regression modeling. For each defined complica-
tion, type of operation, age, gender, use of heparin-coated or
uncoated CPB circuit, Higgins’ score, body weight, aortic
occlusion time, duration of CPB, and the activation parame-
ters were entered into multivariate logistic regression model
fittings, as well as possibly relevant variables identified in
univariate logistic regression. Near-significant variables (P
values between .05 and .10) were kept in the model if
removal substantially reduced model fit, and goodness-of-fit
was assessed by the Hosmer-Lemeshow test. Linearity of the
logits for all continuous variables was checked by plotting
and, if necessary, transformations were applied to achieve lin-
earity. The variables were scaled by the following factors to
achieve a reasonable size of the coefficients: LF area in
model for infections: 10–3, TCC area in models for cardiac
and central nervous system dysfunction: 10–3, square of LF
area in model for renal dysfunction: 10–6.
Linear regression modeling. The dependent variables for
complement activation were maximal C3bc, C3bc area, max-
imal TCC, and TCC area after logarithmic transformation.
The independent variables were age, gender, scheduled type
of operation, height, weight, Higgins’ score, heparin-coated
or uncoated CPB set, and the intraoperative variables heparin
and protamine doses, duration of aortic occlusion and CPB,
and whether the patient required more than one attempt at
weaning from CPB. After fitting the best model, we tested
whether the model was significantly improved by inclusion
of antigen C3, antigen C4, CH50-c, and CH50-a. The depen-
dent variables for granulocyte activation were maximal MPO,
MPO area, maximal LF, and LF area after logarithmic trans-
formation. The independent variables were age, gender,
scheduled type of operation, height, weight, Higgins’ score,
heparin-coated or uncoated CPB set, aortic occlusion time,
duration of CPB, duration of CPB after release of aortic
crossclamp, doses of heparin and protamine, relationship of
heparin/protamine, C3bc area, TCC area, BTG area, and
endotoxin concentration at termination of CPB. For all mod-
els, residual plots were examined and, if necessary, explana-
tory variables were transformed. Some variables were scaled
by a factor of 10–1 to 10–5 to achieve a reasonable size of the
coefficients. 
